Stomach balloon shows promise for fatty liver – but more proof needed

NCT ID NCT07493967

ENROLLING_BY_INVITATION Disease control Sponsor: Methodist Health System Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 200 people with nonalcoholic fatty liver disease (NAFLD) who receive an intragastric balloon—a device placed in the stomach to help with weight loss. Researchers will track changes in weight, liver enzymes, blood sugar, and liver stiffness for at least one year. The goal is to see if the balloon improves both liver health and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: intragastric balloon
What this could lead to: If successful, this could show that intragastric balloon placement helps manage NAFLD by promoting weight loss and improving liver health.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove cause and effect. The balloon carries risks like discomfort, nausea, or rare complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAFLD

Contacts and locations

Locations

Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.